Tag: Prescription Drugs

Displaying 1 - 20 of 219 results.

Pages

The Federal Trade Commission announced its Opinion and Final Order against generic pharmaceutical company Impax Laboratories LLC.
The Federal Trade Commission has approved an application by Teva to reopen and modify its decision and order in connection with the 2012 merger of Watson Pharmaceuticals, Inc. and Actavis Inc.
The Federal Trade Commission is currently accepting public comments on an application by Teva Pharmaceutical Industries Ltd. requesting that the Commission reopen and modify its decision and order in connection with the 2012 merger of Watson Pharmaceuticals, Inc. and Actavis Inc.
Federal Trade Commission Chairman Joe Simons issued the following statement regarding the decision by the U.S. District Court for the Eastern District of Pennsylvania in the case FTC v. AbbVie. The court ruled that AbbVie used sham litigation to illegally maintain its monopoly over the testosterone...
In an Initial Decision announced on May 18, 2018, Chief Administrative Law Judge D. Michael Chappell dismissed the antitrust charges in a complaint issued by the Federal Trade Commission against generic pharmaceutical company Impax Laboratories, Inc.
Letter From Markus H. Meier, Assistant Director, Health Care Division, Bureau of Competition, to Jennifer R. Bolster, Esq., Hancock Estabrook, LLP, Concerning Crouse Health Hospital's Proposal To Sell Discounted Pharmaceutical Products to the Employees, Retirees, and Their Dependents...
WHAT:The Federal Trade Commission will host a workshop, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics”. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr.
The staff of the Federal Trade Commission has issued an opinion advising Crouse Health Hospital that an exemption under the Non-Profit Institutions Act, or NPIA, applied to its proposal to sell discounted pharmaceutical products to the employees and retirees, as well as their dependents, of its...
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” will take place on November 8, 2017 at the FTC’s...
The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses.
The Hatch-Waxman Act, passed by Congress more than 30 years ago, provides a regulatory and judicial framework to expedite generic entry into U.S. prescription drug markets. For many drugs, the Act has succeeded in lowering patent-related barriers to generic drug entry, thereby...

Pages